Particle.news
Download on the App Store
13 ARTICLES
·
last mo.

FDA Reinstates Dr. Vinay Prasad as Biologics Chief Less Than Two Weeks After Resignation

HHS confirms he will lead vaccine and gene therapy reviews following pressure from Commissioner Marty Makary

In this undated photo provided by the US Food and Drug Administration, Vinay Prasad smiles for a portrait.
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
Dr. Vinay Prasad, a prominent UCSF oncologist and outspoken critic of the U.S. government’s past pandemic policies, has been reinstated at his senior post at the Food and Drug Administration less than two weeks after resigning under pressure.
Laura Loomer is seen outside the U.S. Capitol on Thursday, June 12, 2025.

Overview

  • The FDA requested Prasad’s return to lead the Center for Biologics Evaluation and Research, HHS spokesman Andrew Nixon said on August 9.
  • He resigned on July 30 after facing criticism from right-wing activist Laura Loomer and other conservative voices and citing a desire to avoid distracting the agency and spend time with his family.
  • Marty Makary appointed Prasad in May, praised his scientific rigor, and publicly urged him to reconsider his resignation.
  • Prasad’s tenure featured stricter COVID-19 vaccine guidelines, including overruling agency reviewers to curb Moderna and Novavax shot authorizations.
  • He oversaw a temporary halt of Sarepta’s Elevidys gene therapy for Duchenne muscular dystrophy over safety concerns before authorizing its shipment resumption on July 28.